发明授权
US07883888B2 Peptides selectively lethal to malignant and transformed mammalian cells
有权
对恶性和转化的哺乳动物细胞选择性致死的肽
- 专利标题： Peptides selectively lethal to malignant and transformed mammalian cells
- 专利标题（中）： 对恶性和转化的哺乳动物细胞选择性致死的肽
-
申请号： US10549048申请日： 2004-01-13
-
公开(公告)号： US07883888B2公开(公告)日： 2011-02-08
- 发明人: Josef Michl , Jesko Koehnke , Matthew R. Pincus
- 申请人： Josef Michl , Jesko Koehnke , Matthew R. Pincus
- 申请人地址： US NY Albany
- 专利权人： The Research Foundation —The State University of New York
- 当前专利权人： The Research Foundation —The State University of New York
- 当前专利权人地址： US NY Albany
- 代理机构： Dilworth & Barrese, LLP
- 国际申请： PCT/US2004/000684 WO 20040113
- 国际公布： WO2004/081030 WO 20040923
- 主分类号： C12N15/00
- IPC分类号： C12N15/00
摘要：
The present invention provides peptides corresponding to all or a portion of amino acid residues 12-26 of human p53 protein, which peptides are lethal to malignant or transformed cells when fused to a membrane-penetrating leader sequence. The subject peptides are thus useful in treating neoplastic disease in an animal, preferably a human. Also provided are pharmaceutical compositions comprising the subject peptides admixed with a pharmaceutical acceptable carrier. Methods of treating neoplastic disease in a patient by administering a subject peptide fused at its carboxy terminal end to a membrane penetrating leader sequence are also provided. The present invention also provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence operably linked to a nucleotide sequence encoding a subject peptide. Methods of selectively killing cancer cells in a subject by administering a therapeutically effective amount of a subject AdV vector are also provided by the present invention.
公开/授权文献
信息查询
IPC分类:
